169 related articles for article (PubMed ID: 33079544)
1. Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β.
Ortega JA; Arencibia JM; Minniti E; Byl JAW; Franco-Ulloa S; Borgogno M; Genna V; Summa M; Bertozzi SM; Bertorelli R; Armirotti A; Minarini A; Sissi C; Osheroff N; De Vivo M
J Med Chem; 2020 Nov; 63(21):12873-12886. PubMed ID: 33079544
[TBL] [Abstract][Full Text] [Related]
2. Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer.
Catanzaro E; Betari N; Arencibia JM; Montanari S; Sissi C; De Simone A; Vassura I; Santini A; Andrisano V; Tumiatti V; De Vivo M; Krysko DV; Rocchi MBL; Fimognari C; Milelli A
Eur J Med Chem; 2020 Sep; 202():112504. PubMed ID: 32712536
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.
Ortega JA; Riccardi L; Minniti E; Borgogno M; Arencibia JM; Greco ML; Minarini A; Sissi C; De Vivo M
J Med Chem; 2018 Feb; 61(3):1375-1379. PubMed ID: 29077404
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 1,2-diphenylethene derivatives as human DNA topoisomerase II catalytic inhibitors and antitumor agents.
Xu G; Li Z; Ding Y; Shen Y
Eur J Med Chem; 2022 Dec; 243():114706. PubMed ID: 36063665
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, Dynamic Docking, Biochemical Characterization, and
Arencibia JM; Brindani N; Franco-Ulloa S; Nigro M; Kuriappan JA; Ottonello G; Bertozzi SM; Summa M; Girotto S; Bertorelli R; Armirotti A; De Vivo M
J Med Chem; 2020 Apr; 63(7):3508-3521. PubMed ID: 32196342
[TBL] [Abstract][Full Text] [Related]
6. Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II.
Kuriappan JA; Osheroff N; De Vivo M
J Chem Inf Model; 2019 Sep; 59(9):4007-4017. PubMed ID: 31449404
[TBL] [Abstract][Full Text] [Related]
7. Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
Ferguson DM; Jacobson BA; Jay-Dixon J; Patel MR; Kratzke RA; Raza A
Anticancer Res; 2015 Oct; 35(10):5211-7. PubMed ID: 26408679
[TBL] [Abstract][Full Text] [Related]
8. Search for human DNA topoisomerase II poisons in the group of 2,5-disubstituted-1,3,4-thiadiazoles.
Plech T; Kaproń B; Paneth A; Wujec M; Czarnomysy R; Bielawska A; Bielawski K; Trotsko N; Kuśmierz E; Paneth P
J Enzyme Inhib Med Chem; 2015 Dec; 30(6):1021-6. PubMed ID: 25792499
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel topoisomerase II alpha inhibitors by virtual screening, molecular docking, and bioassay.
Yu C; Hu J; Luyten W; Sun D; Jiang T
Chem Biol Drug Des; 2022 Jan; 99(1):92-102. PubMed ID: 34310071
[TBL] [Abstract][Full Text] [Related]
10. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Kassab AE; Gedawy EM
Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological research of novel azaacridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
Li D; Yuan Z; Chen S; Zhang C; Song L; Gao C; Chen Y; Tan C; Jiang Y
Bioorg Med Chem; 2017 Jul; 25(13):3437-3446. PubMed ID: 28511910
[TBL] [Abstract][Full Text] [Related]
12. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
13. An optimized polyamine moiety boosts the potency of human type II topoisomerase poisons as quantified by comparative analysis centered on the clinical candidate F14512.
Palermo G; Minniti E; Greco ML; Riccardi L; Simoni E; Convertino M; Marchetti C; Rosini M; Sissi C; Minarini A; De Vivo M
Chem Commun (Camb); 2015 Oct; 51(76):14310-3. PubMed ID: 26234198
[TBL] [Abstract][Full Text] [Related]
14. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors.
Bergant K; Janezic M; Perdih A
Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675
[TBL] [Abstract][Full Text] [Related]
15. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ.
Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N
Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062
[TBL] [Abstract][Full Text] [Related]
16. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
[TBL] [Abstract][Full Text] [Related]
18. Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile.
Khalil OM; Gedawy EM; El-Malah AA; Adly ME
Bioorg Chem; 2019 Mar; 83():262-276. PubMed ID: 30391699
[TBL] [Abstract][Full Text] [Related]
19. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N
Bioorg Med Chem Lett; 2017 Feb; 27(3):586-589. PubMed ID: 27998679
[TBL] [Abstract][Full Text] [Related]
20. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
